Now, it’s worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 194% for ...

Cidara Therapeutics (CDTX) stock rocketed higher on Friday after the biotechnology company announced it will be acquired by ...

Cidara Therapeutics (CDTX) stock surge 100% as Merck acquires biotech for $9.2B at $221.50 per share, triple its previous ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers ...

Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in ...

Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...

Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting ...

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain ...

Investing.com-- Merck & Company Inc (NYSE: MRK ) is close to a deal to buy flu treatment maker Cidara Therapeutics Inc (NASDAQ: CDTX) after pulling ahead of rivals in a bidding war for the firm, the ...